4,4 DIALKYL-4-SILA-FATTY ACID AMIDES, INTERMEDIATES AND PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Abstract: Novel compounds of the formula in which each of R₁, R₂ and R₃ are independently alkyl, and R is an optionally substituted aralkyl, phenyl, indolyl or benzocycloalkyl radical. They are prepared by acylating a corresponding com­ pound of formula H₂N-R with a corresponding compound or a reactive derivative thereof. The 4-sila carboxylic acids are novel and are prepared in via intermediates of which several are novel and in which the carboxylic radical is replaced by a methylol resp. a boron containing methylene group. The compounds I are useful as anti-atherosclerotic agents.

Description: 4,4-DIMETHYL-4-SILA-FATTY ACID AMIDES, THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS The present invention provides compounds of formula I: EMI1.1 in which each of R1, R2 and R3 is independently (C1-22)alkyl, R is a) an aralkyl radical of the formula EMI1.2 in which g represents 0, 1 or 2, Ra is hydrogen, fluorine, chlorine, bromine or iodine, (C1 4)alkyl or alkoxy or tri fl uoromethyl, Rb is hydrogen, fluorine or chlorine, or (C1-3)alkyl or alkoxy, Rc is i) hydrogen ii) a radical of the formula EMI2.1 in which p is 0, 1 or 2, and Y is hydrogen, fluor ine, chlorine, bromine or iodine, or (C1 4)alkyl or alkoxy, Y' is hydrogen, fluor ine or chlorine or (C13)alkyl or alkoxy, or iii) (C1-8)alkyl, or R is b) a phenyl radical of the formula EMI2.2 in which Rb is as defined under a) and Ro is hydrogen, fluorine, chlorine, bromine or iodine or (C1-4)alk- yl or alkoxy or a radical Rf, EMI2.3 in which D is -CH2- or -0 f is O or 1, and W is hydrogen, fluor ine, chlorine or bromine or (C1-3) alkyl or alkoxy, or R is c) an indolyl radical of the formula EMI3.1 in which Rb is as defined under a) R4 is (C1-8)alkyl or unsubstitu ted benzyl, and R5 is hydrogen, (C18)alkyl or unsubstituted benzyl, or R is d) a benzocycloalkyl radical of the formula EMI3.2 in which Y and Y' are as defined under a) and j is from 1 to 4. The preferred compounds of formula I are those of formula Ia, EMI4.1 in which R1' is C1-22alkyl, in which any branching is on other than the a-carbon atom, Ra is as defined above, and Rc0 is EMI4.2 in which V" is fluorine, chlorine, bromine or iodine, or (C1 4)alkyl. Especially preferred compounds of formula Ia are those in which R1' is (C522)alkyl in which any branching is on other than the a-carbon atom such as straight chain (C5-22)alkyl, particul arly (C8-18)alkyl, especially (C8-14)alkyl, more especially (C10-alkyl; Ra is hydrogen; and Y" is methyl. A second group of compounds are those of formula Ib, EMI4.3 in which Rj and Ra are as defined above, and Rc2 is (C14)alkyl. Especially preferred compounds Ib are those in which Rj is straight chain (C818)alkyl, particularly (C1O 8)- alkyl, and Ra is hydrogen. RC2 is preferably methyl. If, in compounds of formula I, R is of type a) or type b) in which R0 is not R?, it is preferred that, when it contains monosubstituted phenyl, the substituent is located at the 4-position and that, when the phenyl is di-substituted, the substituents are the same and are preferably located at the 2- and 4-positions of the phenyl ring. When R is of type a), where g = 1 and Rc is of.type ii) where p = 0, then R can be an a-(phenyl)-ss-(p-methylphenyl)ethyl radical and when Rc is of type ii) where p = 1, then R can be a o^(benzyl)- phenylethyl radical. When R is ofXtype b) and R0 is Rf, then Rf is preferably at the para-position. When W is other than hydrogen, it is preferably at the para-position. When R is of type c), it is preferred that, when the phenyl ring is mono-substituted, the substituent be located at the 5-position of the indole nucleus. It is also preferred that when R4 is alkyl, it is unbranched, particularly ethyl. When R is of type d), it is preferred that when Y is other than a hydrogen atom, that it be located at a carbon atom ortho to the ring junction and that when Y' is also other than a hydrogen, it is preferred that it be the same as Y,and it is additionally preferred that it be in para position to Y. It is additionally preferred that the amide group be linked to a carbon of the cycloalkyl moiety which is directly bonded to a ring junction carbon. It is also preferred that j be 1, i.e. that the benzocycloalkyl nucleus be indanyl and particularly 1-indanyl. In the above-presented definitions, when Rb, Ra qr Y is halo, it is preferably fluorine or chlorine and particularly chlorine, and when R2 or Y' is halo, it is preferably chlorine. The invention also provides a process for the preparation of the compounds of formula I, characterised by acylating a compound of formula III, H2N - R III with a compound of formula IV, EMI6.1 or a reactive derivative thereof, R, R1, R2 and.R being as defined above. The reaction conditions for this type of acylation reaction are known per se. Suitable derivatives of compounds IV include acid chlorides, active esters, a carbodiimide adduct or mixed anhydrides. - The acylating agent is preferably of the formula EMI7.1 in which R6 is (C1-4)alkyl and R1, R2, R3 are as defined above. This process may be carried out neat or in the presence of an inert organic solvent such as an ether, a halogenated hydrocarbon, e.g., methylene dichloride, chloroform, or an excess of a compound of the formula III. Methylene chloride is preferred as a solvent. The temperature of the reaction is not critical, but is preferably from about 500to +300C., preferably from about -100 to +200C. The reaction is suitably run from about 1 to 72 hours, preferably from about 4 to 16 hours. The resulting compounds I may be isolated and purified using conventional techniques. The compounds of formula II may be prepared according to the following reaction scheme: EMI8.1 in which R1, R9, R3 and R6 are as defined above, 8 is boron, R8 and R9 each independently represent hydrogen or (C1-8)alkyl or R8 and R9 together are EMI8.2 EMI9.1 n is 1 to 3, and (R,)3-n is [(Cl E(C ,g)al kyl] 3-n Or' alternatively EMI9.2 In reaction step d) preferred acid binding agents include pyridine, triethylamine and diisopropylamine, preferably tri ethyl amine. Preferred solvents are aprotic solvents, such as the halogenated hydrocarbons, e.g. methylene dichloride, chloroform, or the aromatic hydrocarbons, e.g. benzene, toluene and acetonitrile. A preferred solvent is methylene dichloride. The reaction temperature is, e.g. from about -50 to +300C, especially from -200 to +200C. The reaction is run, e.g. from about 10 minutes to 18 hours, preferably from about 30 minutes to 3 hours. The product may be recovered by conventional techniques. However, the compounds of the formula II are suitably not isolated but used in situ in the preparation of the final compounds. In step c) the compound of the formula VI is reacted with an oxidising agent such as potassium permanganate or, preferably, chromium trioxide, suitably under acidic conditions. Preferred acids include the mineral acids, such as phosphoric acid, acetic acid or especially sulfuric acid. A suitable solvent is acetone, especially acetone in combination with a small amount of water, although the combination of water and other inert solvents, such as diethylether, may also be employed. The temperature of the reaction is preferably from about -400 to +300C, especially from -100 to +50C. The reaction is run from, e.g. about 10 minutes to 6 hours, preferably from 2 to 3 hours. In step b) compounds of formula VII are reacted with water, in a first step with an organic or inorganic base and in a second step with a hydroperoxide, e.g. a tertiary lower alkyl hydrbperoxide or hydrogen hydroperoxide, preferably t-butyl hydroperoxide, in an inert organic solvent. . Suitable bases include organic bases such as methyldiisopropylamine, pyridine or, preferably, triethylamine. Less preferred are the inorganic bases- such as alkali metal hydroxides. The preferred solvents include dioxane, diethylether or preferably tetryhydrofuran. The temperature of the reaction is preferably from about -200 to +400C, especially from Oo to 250C. The reaction is run from e.g. about 3 to 24 hours, preferably from about 12 to 16 hours. The reaction step a) may suitably be performed under an inert atmosphere, e.g. nitrogen, and in the presence of an aprotic solvent. The boron reagent IX contains at least one active hydrogen atom, and is e.g. BH3 or an alkyl boron hydride, or other boron hydrides conventionally used for hydroboration, e.g. 9-borabicyclo[3.3.llnonane of the formula EMI10.1 or catecol-borane of the structure EMI11.1 The agent is preferably used in the form of a tetrahydrofuran/borane reagent (1:1) e.g. (BH3.THF). Preferred aprotic solvents are ethers such as diethylether or tetrahydrofuran, the latter being especially preferred. The temperature of the reaction is preferably from about 780 to +100 C, especially from about -100 to +300C. The reaction is run from e.g. about 5 minutes to 12 hours, preferably from about 15 minutes to 1 hour. The product may be recovered using conventional techniques, however, it is preferred that compound VII not be isolated but employed in situ in the preparation of compounds VI. Many of the compounds VIII are known or may be prepared by conventional techniques, e.g. metal organic displacements of halogen on silicon. The compounds of formula III, V and IX are either known or may be prepared in conventional manner from available materials. The compounds of formula IV, VI and VII, in which R1 represents (C5 22)alkyl, particularly (C818)alkyl, are novel and also form Dart of the present invention. Of more particular interest among said novel compounds are those in which any branching of R1 is on other than the carbon atom and also those in which R1 is straight chain (C5 22)alkyl, particularly (Cg-18)alkyl and especially those in which R2 and R3 are both methyl. It will be understood that the compounds of formula I may exist in the form of optically active isomers, e.g., enantiomers, which can be prepared from optically active compounds III or separated and recovered by conventional techniques, i.e., resolution. Such isomeric forms are also included within the scope of this invention. The compounds of formula I of this invention possess pharmacological activity. In particular the compounds of the formula I are indicated for use in controlling the chloresterol ester content of mammalian arterial walls and are therefore particularly indicated for use as anti-atherosclerotic agents,t.e. agents useful in the prophylactic treatment of atherosclerosis and in the controlling of atherosclerotic conditions due to chloresterol ester accumulation in the arterial walls. Such ability of the compounds of the formula I is indicated by known test procedures in which the total chloresterol ester content of cultured cells is shown to be reduced by a test compound, as compared to untreated cells, and carried out, for example, by the following procedures: A) CELL CULTURE Rhesus monkey smooth muscle cells (from the arterial, e.g., aorta, wall) obtained by the method of K. Fischer-Dzoga et al. [Experimental and Molecular Pathology 18, 162-176 (19730 are routinely groin in 75 cm2 tissue culture flasks using Minimum Essential Medium (Eagle) supplemented with 10 foetal bovine serum. For testing a 75 cm flask with a near confluent cell growth is selected. The cells are removed from the flask surface by mild enzymatic treatment with pronase. After centrifugation and decanting the enzyme solution, the cell pellet is resuspended in an appropriate volume of media for seeding the desired number of 60 mm tissue culture dishes. Five (5) ml of the diluted cell suspension are pipetted into each dish. After seeding, the dishes are labelled with the cell type, date and flask number of origin and incubated at 370C in approximately 5% C02 atmosphere in a high humidity incubator. When the cultures are confluent, the actual drug testing is begun. Test compounds are routinely solubilized in 100% ethanol. An equivalent amount of ethanol is added to control groups as well. The tissue culture dishes are randomly divided into groups. To one group, hyperlipemic rabbit serum (HRS) is added at 5% by volume (control). To the remaining groups, 5% HRS and 0,1 to 1 mg per 100 ml of media of the test compound are added. The dishes are returned to the incubator for an additional 24 hours. All operations through to the final incubation are performed using sterile technique in a laminar flow hood. After the incubation period, the dishes are microscopically observed with the Zeiss Axiomat with phase contrast optics and the conditions of the cultures are recorded; especially in regard to the size, number and configuration of cytoplasmic inclusions and to cellular morphology. The media is removed from the cultures and 0.9% sodium chloride solution is added. The cells are removed from the flasks with the aid of a rubber policeman and transferred to a conical granuated centrifuge tube. The cells are washed three times by suspending in an- isotonic salt solution, centrifuging at 800 x g for 10 minutes and aspirating the supernatant fluid. B) CELL EXTRACTION PROCEDURE An appropriate volume of isopropyl alcohol (about 1 ml/mg protein) is then added to the cell pellet and the sample sonicated with a micro probe (140 x 3 mm) for 10 seconds with a "LO" setting of 50 on a Bronwell Biosonik IV. After centrifugation for 15 minutes at 800 x g, the clear supernatant is decanted and an-aliquot taken for cholesterol analysis. The residue is dissolved in 0.lN sodium hydroxide and an aliquot taken for protein determination by the method of Lowry et al. (J. Biol. Chem. 193 , 265; 1951). C) ASSAY Free cholesterol: The isopropyl alcoholic solutions of standards, samples and blank (isopropyl alcohol alone) are treated in a similar manner. An aliquot of 0.4 ml of free agent (Reagent A, Table 1 below) is added to a 10 x 75 mm disposable glass test tube to which 20 1 of the isopropyl alcoholic solution is added and mixed. After standing at room temperature for approximately 5 minutes, 0.8 ml of 0.5N sodium hydroxide (Reagent C, Table 1) is added and mixed. The fluorescence is measured with an Aminco-Bowman Spectrophotofluorometer with an excitation wavelength of 325 nm and emission wavelenght of 415 nm. A 1 cm light path cuvette is used with a Xenon lamp, an IP28 Photomultiplier tube and 2 mm slits. Total cholesterol: The same procedure described above for free cholesterol is followed for total cholesterol except that the total reagent (Reagent B, Table 1) is used instead of the reagent and the samples are incubated for 20 minutes at 370 C before the addition of the 0.5N sodium hydroxide solution (Reagent C, Table 1). Alternatively, the assay for cholesterol, i.e. Step C) (above) obtained from Steps A) and B), may be carried out by the method'of Ishikawa et al (J. Lipid Res. 15, 286; 1974). The amount of cholesterol ester is found by subtracting the amount of free cholesterol from the total cholesterol content of the cells determined by the assay. A finding of a lower amount of cholesterol ester in the group of cells to which the test compound was added, as compared to the control group (untreated) shows that the test compound is active in reducing the cholesterol ester in the cells. TABLE 1 Composition of Reagents for Cholesterol Determination A. Free Cholesterol Reagent Sodium phosphate buffer pH 7.0 0,05 M Cholesterol oxidase 0,08 U/ml Horseradish peroxidase 30,00 U/ml p-Hydroxyphenylacetic acid \ 0,10 mg/ml B. Total Cholesterol Reagent Sodium phosphate buffer pH 7.0 0,05 M Cholesterol ester hydrolase 0,08 U/ml Cholesterol oxidase 0,08 U/ml Horseradish peroxidase 30,00 U/ml Sodium taurocholate 5,00 mM Carbowax-6000 0,17 mM p-Hydroxyphenylacetic acid 0,15 mg/ml C. Sodium Hydroxide Solution 0,5N For the above-mentioned use, an indicated suitable daily dosage is from 10 mg to about 5,000 mg, suitably administered in divided doses of 2.5 to 2,500 mg, two to four times daily or in retard form. Fpr the use of compounds of formula Ia, an indicated suitable daily dosage is from about 10 mg to about 1,000 mg, suitably administered in divided doses of from 2.5 to 500 mg, two to four times daily or in retard form. With respect to compounds of formula Ib, an indicated suitable daily dosage is from about 100 mg to about 5,000 mg, preferably from about 100 mg to 2,000 mg and suitably administered in divided doses of from 25 to 2,500 mg, two to four times daily or in retard form. The compounds may be admixed with conventional pharmaceutically acceptable diluents and carriers and, optionally, other excipients, and administered in such forms as tablets or capsules. The following Preparations and Examples illustrate the invention. PREPARATION 1: 4,4-dimethyl-4-sila-tetradecene-1. Compound VIII Under nitrogen, 205 g (0.928 mole) of l-bromodecane is added to a stirred mixture of 73 g of magnesium turnings (3.04 mole), 570 ml of absolute tetrahydrofuran and 183 g (172 ml, 1.42 mole) of dimethyldichlorosilane at such a rate that after initiation, with external cooling, the reaction temperature does not rise above 400 C. After addition and the completion of the exothermic reaction, the mixture is stirred for 1 hour at 400C. A Gilman test on a sample shows that all Grignard reagent is consumed. The resulting mixture is concentrated in vacuo under strictly anhydrous conditions. The resulting semi-solid mass is stirred at about 450 to 650C while 218 g (1.8 mole) of allyl bromide and 400 ml of absolute tetrahydrofuran are added. The exothermic reaction is controlled by cooling. Stirring is continued at 600 for 16 hours. The mixture is then cooled, 2 1 of hexane are then added, and the contents poured into 318 g of ammonium chloride dissolved in water plus ice. The organic phase is separated after addition of some ligroin. The product is then washed with three portions of water, dried with anhydrous sodium sulfate, filtered and concentrated in vacuo . The crude product is fractionated through a packed column to obtain fractions of 4,4-dimethyl-4-sila-tetradecene-l; b.p. 69-810/0.015- 0.030 mm Hg. PREPARATION 2: 4,4-dimethyl-4-sila-tetradecanol. Compound VI Under nitrogen 270 ml of 1M borane in tetrahydrofuran (0.81 equivalents) are added while maintaining the temperature below 250C to 166.4 g (0.69 mole) of 4,4-dimethyl-4-sila-tetradecene-l in 550 ml of absolute tetrahydrofuran. The reaction mixture is allowed to stand for 1/2 hour at 200C,then 10 ml of water are carefully added to react away excess hydride (H2 evolution). When gas evolution ceases, 140 g (1.39 mole) of triethylamine are added, followed by 93 g (1.03 mole) of trt-butyl hydroperoxide with cooling to 5 - 200C (exothermic). The reaction mixture is then allowed to stand at 200C for 16 hours and concentrated in vacuo below 4OOC. The concentrate is distributed between toluene and dilute aqueous sodium hydroxide, the organic phase is washed with more sodium hydroxide, twice with water, twice with slightly acidified (HC1) ferrous sulfate solution (to remove any remaining peroxide), twice with dilute hydrochloric acid and once with sodium bicarbonate solution, dried over sodium sulfate, filtered and concentrated in vacuo to give a colorless oil which is then fractionated in vacuo through a column containing a stainless steel protruded packing to obtain the title product; ; b.p. 1100-1140C/0.035 mm. PREPARATION 3: 4,4-dimethyl-4-sila-tetradecanoic acid. Compound IV A solution of 143.4 g (0.554 mole) of 4,4-dimethyl-4-silatetradecanol in 1.2 1 of acetone is cooled to -100C. With cooling to -10 to OOC and stirring, 302 ml of Jones reagent (8N in oxidation equivalents of chromic acid in aqueous sulfuric acid) (4.36 x 0.554 electron equivalents) are added over a period of 30 minutes. Stirring is continued at -10 to OOC for 45 minutes, and at O to 50C for 1 hour. While stirring, the mixture is allowed to warm to 100C in 1/2 hour after which it is poured on ice plus heptane. The organic phase is washed three times with a semi saturated sodium chloride solution, twice with water, dried over sodium sulfate, filtered and concentrated in vacuo to yield an oil. Most of the resulting material is fractionally distilled through a column packed with a stainless steel protruded packing to give the title product; b.p. 138-14OOC/ 0.05 mm. PREPARATIONS 4 - 21: Following the above procedures and using corresponding starting materials in equivalent amounts, the following products (in which R2 and R3 are CH3) are obtained: Substituent Preparation of Preparation of Preparation of R1 Compounds VIII Compounds VI Compounds IV CH- 4 10 16 CH3-(CH2)2 5 11 17 CH3-(CH2)4- 6 12 18 CH3-(CH2)6 7 13 19 CH3-(CH2)7 8 14 20 CH3-(CH2)17 9 15 b.p.178-1820C 21 m.p.43 at 0.035 mm 450C EXAMPLE 1 (+)-4,4-dimethyl-4-sila-tetradecanoyl-l '-phenyl-ethylamide. Compound I To 35 g (128.5 m mole) of 4,4 -dimethyl-4-sila-tetradecanoic acid in 200 ml of methylene dichloride there are adder 14.3 g (128.5 m mole) of triethylamine while maintaining the temperature between 20 to 300C(exothermic). The resultant clear solution is maintained at Oo to -200C while 15.4 g (128.5 m mole) of ethylchloroformate in 100 ml of methylene chloride are added, yielding the mixed anhydride of the formula II. The resultant mixture is then allowed to come to a temperature of 15 C over a period of 3/4 hour, and then 34.4 g (2 x 1.1 x 128.5 m mole) of (+)-$methylbenzylamine are added with continued stirring while maintaining the temperature below 200C. The mixture is subsequently stirred at 200C for 3 hours, then poured on ice. The organic phase is washed twice with 1N hydrochloric acid and once with a mixture of sodium bicarbonate and sodium carbonate solution, dried with sodium sulfate, filtered and concentrated in vacuo to give 47.2 g of an oil. Evaporative distillation using a "Kugelrohr" device gives the microanalytically pure title product; m.p. 32 to 340C,as the last fraction, from a temperature of 170-177 C at 0.06 mm Hg. EXAMPLE 2 (+-) -4 ,4-Dimethyl -4-si 1 a-tetradecanoyl -l '-phenyl -2 1-p-tolyl ethylamide (Compound I) To a dry flask there is added 3.17 g (11.6 ni mole) of 4,4-dimethyl-4-sila-tetradecanoic acid, 2.53 g (23.2 m mole) of triethylamine and 5 ml of methylene dichloride. The resulting solution is cooled in an ice bath. With stirring and while maintaining the temperature at OOC, a solution of 1.385 9 (12.8 m mole) of ethylchloroformate in 3 ml of methylene dichlor ide is added in approximately one minute and the resulting solution is then treated with 2 ml of methylene dichloride. The resultant white slurry is stirred at OOC for one hour. A solution of 2.45 g (11.6 m mole) of (f)l-phenyl-2-e-tolylethylamine in 3ml of methylene dichloride is then added with stirring in the ice bath followed by 2 ml of methylene dichloride rinse. The resulting mixture is allowed to warm to room temperature while maintaining stirring. Gentle stirring is continued for an additional 48 hours. The reaction mixture is then washed with approximately 25 ml of water following which the organic phase is extracted with dilute hydrochloric acid until the aqueous extract is acidic. The organic phase is then washed with a sodium bicarbonate solution (pH = 8), dried with anhydrous sodium sulphate, filtered and concentrated in vacuo at 40 C to yield a colourless oil. This oil was chromatographed on silica gel eluting with 1:1 hexane: chloroform, to obtain the title compound, m.p. 39-42 . Following the procedure of Examples 1 and 2 and using corresponding starting materials in nearly equivalent amounts, the following products of formula I (in which R2 and R3 are methyl) are obtained: EMI24.1 <tb> <SEP> Ex. <SEP> acc. <SEP> Substi <SEP> tuent <SEP> R1 <SEP> Substituent <SEP> R <SEP> Characteristics <tb> <SEP> 3 <SEP> | <SEP> 2 <SEP> CH3-(CH2)17- <SEP> -CH-CH2H3 <SEP> $ <SEP> m.p. <SEP> m.p. <SEP> 64-650C <tb> (DI <tb> <SEP> 4 <SEP> 2 <SEP> CH3- <SEP> " <SEP> m.p. <SEP> 91-95 C <tb> <SEP> 5 <SEP> 2 <SEP> CH3-(CH2)2- <SEP> .. <SEP> (+), <SEP> oil <tb> <SEP> 6 <SEP> 2 <SEP> CH3-(CH2)7- <SEP> .. <SEP> (f), <SEP> oil <tb> <SEP> 7 <SEP> 2 <SEP> CH3-(CH2)9- <SEP> II <SEP> (+) <tb> <SEP> 8 <SEP> 2 <SEP> .. <SEP> .. <SEP> () <tb> <SEP> 9 <SEP> 2 <SEP> ;, <SEP> -CH-CH2tF <SEP> (+-) <tb> <SEP> 10 <SEP> 2 <SEP> .. <SEP> -CH-CH2eC1 <SEP> (+) <tb> <SEP> d <tb> <SEP> 11 <SEP> 2 <SEP> .. <SEP> -CH24 <tb> <SEP> 12 <SEP> 2 <SEP> CH3- <SEP> .. <SEP> oil <tb> <SEP> 13 <SEP> 1 <SEP> CH3-(CH2)17- <SEP> -CH-CH3 <SEP> (+). <tb> <SEP> t <SEP> m.p. <SEP> 61-62 <SEP> C <tb> <SEP> 14 <SEP> 1 <SEP> CH3-(CH2)4- <SEP> .. <SEP> (+) <tb> <SEP> 75 <SEP> 1 <SEP> CH3-(CH2)6- <SEP> " <SEP> (+) <tb> <SEP> 16 <SEP> 1 <SEP> CH3-(CH2)9- <SEP> ', <SEP> (-) <tb> <SEP> 17 <SEP> 1 <SEP> ll <SEP> ll <SEP> (+) <tb> EMI25.1 <tb> <SEP> Prep. <tb> Ex. <SEP> acc. <SEP> SubstituentR <SEP> Substituent <SEP> R <SEP> Characteristics <tb> <SEP> to-Ex. <SEP> :1 <tb> 18 <SEP> 1 <SEP> CH3-(CH2)9- <SEP> QClH-CH3 <SEP> (+) <tb> <SEP> )si <tb> <SEP> Cl <tb> 19 <SEP> 1 <SEP> .. <SEP> -CH-CH3 <SEP> (+) <tb> <SEP> (Dsi <tb> <SEP> F <tb> 20 <SEP> 1 <SEP> .. <SEP> -CH-CH3 <SEP> (+) <tb> <SEP> )H'3 <tb> 21 <SEP> 1 <SEP> n <SEP> -CK-CH3 <SEP> (+) <tb> <SEP> OCH3 <tb> 22 <SEP> t <SEP> 1 <SEP> -CH-CH, <SEP> (+) <tb> <SEP> CF3 <tb> <SEP> CH3 <tb> 23 <SEP> 2 <SEP> CH3-9H3 <SEP> -CH243 <SEP> CH <SEP> (fj <SEP> oil <tb> <SEP> (· <tb> 24 <SEP> i <SEP> 2 <SEP> 4 <SEP> CH3-(CH2)9 EMI26.1 <tb> <SEP> Prep. <SEP> Substituen <tb> <SEP> b <tb> Ex <SEP> acc. <SEP> R1 <SEP> Substituent <SEP> R <SEP> Characteristics <tb> <SEP> to.Ex <tb> 25 <SEP> 2 <SEP> CH3-(CH2)9 <SEP> -CH-CH2 <SEP> (+). <SEP> m.P. <SEP> 54QC <tb> <SEP> O C2H5 <SEP> H <tb> <SEP> 26 <SEP> 2 <SEP> .. <SEP> ¯CIH <SEP> (t) <tb> <SEP> H3 <tb> <SEP> CH <tb> 27 <SEP> 2 <SEP> is <tb> 28 <SEP> 2 <SEP> ¯CCHH <SEP> 4 <tb> <SEP> CH2 <tb> <SEP> C <SEP> 2 <tb> ¯ <SEP> X <SEP> 3 <tb> In the following table are given NMR values for oily compounds of the invention. The values are expressed in ppm, based on the reference compound tetramethylsilane at 0 ppm, the solvent is CDC13 (D = deuterium). In the table the following symbols are used: s - singlet, d - doublet, q - quartet, m - multiple, and b - broad, numbers given in parenthesis are number of protons. EMI27.1 <tb> Ex. <SEP> NMR <SEP> values <tb> <SEP> 5 <SEP> m <SEP> 7.2(5), <SEP> s <SEP> 6.95(4), <SEP> d <SEP> 5.86(1), <SEP> q <SEP> 5.2(1), <SEP> d <SEP> 3.03(2), <tb> <SEP> s <SEP> 2.25(3), <SEP> m <SEP> 2.0(2), <SEP> m <SEP> 1.25(2), <SEP> m <SEP> 0.9(3), <SEP> m <SEP> 0.5(2plus2) <tb> <SEP> s <SEP> -0.07(6) <tb> 6 <SEP> s <SEP> 7.35(5), <SEP> s <SEP> 7.08(4), <SEP> d <SEP> 6.07(1), <SEP> q <SEP> 5.35(1), <SEP> d <SEP> 3.15(2), <tb> <SEP> s <SEP> 2.35(3), <SEP> m <SEP> 2.2(2), <SEP> s <SEP> 1.3(12), <SEP> m <SEP> 1.0(3), <SEP> m <SEP> 0.6, <SEP> 0.2(2) <tb> <SEP> plus <SEP> (2), <SEP> s <SEP> 0.0(6) <tb> 12 <SEP> s <SEP> 7.15(5), <SEP> b <SEP> 6.35(1), <SEP> d <SEP> 4.26(2), <SEP> m <SEP> 2.07(2), <SEP> m <SEP> 0.74(2), <tb> <SEP> s <SEP> -0.1(9) <tb> 23 <SEP> s <SEP> 7.2(5), <SEP> s <SEP> 6.9(4), <SEP> d <SEP> 5.8(1), <SEP> q <SEP> 5.18(1), <SEP> d <SEP> 2.95(2), <tb> <SEP> s <SEP> 2.17(3), <SEP> m <SEP> 2.0(2), <SEP> s <SEP> 0.75(9), <SEP> m <SEP> 0;55(2), <SEP> s <SEP> -0.2(6) <tb>

Claims: WHAT IS CLAIMED IS: 1. A process for the preparation of a compound of formula I, EMI28.1 in which each of R1, R2 and R3 is independently (C1-22)alkyl, R is a) an aralkyl radical of the formula EMI28.2 in which g represents 0, 1 or 2, Ra is hydrogen, fluorine, chlorine* bromine or iodine, (C1-4)alkyl or alkoxy or trifluoromethyl, Rb is hydrogen, fluorine or chlorine, or (C13)alkyl or alkoxy, Rc is i) hydrogen ij) a radical of the formula EMI29.1 in which p is 0, 1 or 2, and Y is hydrogen, fluor ine, chlorine, bromine or iodine, or (Cl 4)alkyl or alkoxy, Y' is hydrogen, fluor ine or chlorine or (C1-3)alkyl or alkoxy, or (ii) (C18)alkyl, or R is b) a phenyl radical of the formula EMI29.2 in which Rb is as defined under a) and R0 is hydrogen, fluorine, chlorine, bromine or iodine or (C14)alk- yl or alkoxy or a radical Rf, EMI29.3 in which D is -CH2- or -0 f is O or 1, and W is hydrogen, fluor ine, chlorine or bromine or (C1-3) alkyl or alkoxy, or R is c) an indolyl radical of the formula EMI30.1 in which Rb is as defined under a) R4 is (C18)alkyl or unsubstitu ted benzyl, and R5 is hydrogen, (C18)alkyl or unsubstituted benzyl, or R is d) a benzocycloalkyl radical of the formula EMI30.2 in which Y and Y' are as defined under a) and j is from 1 to 4, characterised by acylating a compound of formula III, H2N-R III with a compound of the formula IV, EMI31.1 or a reactive derivative thereof, R, R1, R2 and R3 being as defined above. 2. A compound of formula 1, stated in Claim 1. 3. A compound of formula Ia, EMI31.2 in which Rj is C1 22al kyl, in which any branching is on other than the carbon atom, Ra is as defined.in Claim 1, EMI31.3 in which Y" is fluorine, chlorine, bromine, or iodine or (Cl 4)alkyl. 4. A compound of formula Ib, EMI31.4 in which R; and Ra are as defined in Claim 3, and RC2 is (Cl 4)alkyl 5. 4,4-Dimethyl-4-sila-tetradecanoyl-l '-phenyl-2'-p-tolylethylamide. 6. A pharmaceutical composition comprising a compound of any one of the preceding claims in association with a pharmaceutically acceptable diluent or carrier. 7. A compound of the formula IV, EMI32.1 in which R1, R2 and R3 are as defined in Claim 1. 8. A compound of formula IV, stated in Claim 7, in which R1 is (C522)alkyl, in which any brar.ching is on other than the a-carbon atom, and R2 and R3 are both methyl. 9. A compound of the formula EMI32.2 in which RO is (C5¯22)alkyl, and R2 and R3 are as defined in Claim 1. 10. A compound of formula VI, stated in Claim 9, in which R01 is (C522)alkyl, in which any branching is on other than the a-carbon atom, and R2 and R3 are both methyl. 11. A compound of the formula VII, EMI33.1 in which R1 , R2 and R3 are as defined in Claim 9, B is boron, and R8 and Rg each independently are EMI33.2 hydrogen or (C1-8)alkyl, or R8 and R9 taken together are EMI33.3 12. A compound of formula VII, stated in Claim 11, in which R1 is (C5-22)alkyl, in which any branching is on other than the a-carbon atom, and R8 and R9- independently are EMI33.4 hydrogen or (C1-8)alkyl and any branching of R1 is on other than the carbon atom.

Inventors: BARCZA, SANDOR
Applicants: SANDOZ AG
Application year: 1979
Main classification: C07F7
IPC codes: C07F5, C07F7